Polymorphism AGT2 (rs4762) is involved in the development of dermatologic events: Proof-of-concept in hepatocellular carcinoma patients treated with sorafenib

Table 1 Baseline characteristics of patients included in each cohort

	BCLC1 cohort	BCLC2 cohort	Northern Italy cohort	Naples cohort
Patients, n	82	79	221	69
Gender (Male)	73 (89.02)	67 (84.81)	184 (83.26)	60 (86.96)
Age (Years)	63 (56-71)	63 (56-72)	69 (60-74)	70 (60-74)
AGT1 (rs699)
AA	26 (31.71)	25 (31.65)	72 (32.58)	22 (31.88)
AG	34 (41.46)	35 (44.3)	101 (45.7)	38 (55.07)
GG	22 (26.83)	19 (24.05)	47 (21.27)	9 (13.04)
NA	0 (0)	0 (0)	1 (0.45)	0 (0)
AGT2 (rs4762)
AA	5 (6.1)	3 (3.8)	5 (2.26)	0 (0)
AG	16 (19.51)	10 (12.66)	44 (19.91)	15 (21.74)
GG	61 (74.39)	66 (83.54)	172 (77.83)	54 (78.26)
AHT (Yes)	37 (45.12)	36 (45.57)	65 (29.41)	45 (65.22)
Diabetes (Yes)	22 (26.83)	28 (35.44)	61 (27.6)	23 (33.33)
HBV (Yes)	10 (12.2)	6 (7.59)	46 (20.81)	12 (17.39)
HCV (Yes)	54 (65.85)	38 (48.1)	111 (50.23)	44 (63.77)
HIV (Yes)	2 (2.44)	1 (1.27)	3 (1.36)	0 (0)
Child-Pugh
A: 5-6	70 (85.37)	63 (79.75)	207 (93.67)	58 (84.06)
B: 7-9	10 (12.2)	11 (13.93)	14 (6.33)	10 (14.49)
Not applicable	2 (2.44)	5 (6.33)	0 (0)	1 (1.45)
ECOG-PS (0)	77 (93.9)	74 (93.67)	155 (70.14)	69 (100)
Ascites (Yes)	11 (13.41)	9 (11.39)	25 (11.31)	14 (20.29)
Encephalopathy (Yes)	0 (0)	0 (0)	11 (4.98)	0 (0)
Extrahepatic spread (Yes)	24 (29.27)	27 (34.18)	79 (35.75)	23 (33.33)
Vascular Invasion (Yes)	22 (26.83)	26 (32.91)	61 (27.6)	31 (44.93)
BCLC (A1 or B / C)	42 (51.22) / 40 (48.78)	36 (45.57) / 43 (54.43)	76 (34.39) / 145 (65.61)	20 (28.99) / 49 (71.01)
Alpha-fetoprotein (ng/mL)	20.5 (7-212.5)	25 (8-228)	100.5 (10-869)	98 (5-1903)
Hemoglobin basal (g/dL)	13.8 (12.95-14.95)	13.1 (11.9-14.5)	12.5 (11.2-14)	13 (11.9-13.9)
Prothrombin time (%)	88.3 (76.5-95.6)	76 (65-88)	NA	84.5 (76-100)
International normalized ratio	NA	NA	1.1 (1-1.22)	1.13 (1.03-1.24)
Total bilirubin (mg/dL)	1 (0.8-1.6)	1.1 (0.6-1.7)	0.9 (0.72-1.3)	0.95 (0.7-1.4)
AST (UI/L)	78 (46-119)	54 (34-84)	NA	52 (35-80)
ALT (UI/L)	72 (35-106.5)	44 (25-65)	43 (23-56)	42 (32-55)
GGT (UI/L)	134.5 (93.5-285.5)	143 (83-264)	NA	96 (48-204)
Albumin (mg/L)	38.5 (35-43)	40 (35-43)	38 (35-40)	3.6 (3.3-4)
Initial dosage of sorafenib (mg)
400	5 (6.1)	2 (2.6)	19 (8.6)	0 (0)
600	0 (0)	0 (0)	5 (2.26)	0 (0)
800	77 (93.9)	77 (97.4)	197 (89.14)	69 (100)

Descriptive statistics are frequencies (%) or median (IQR: Interquartile range), as appropriate. AHT: Arterial Hypertension; HCV: Hepatitis C Virus; HBV: Hepatitis B Virus; HIV: Human immunodeficiency virus; AST: Aspartate aminotransferase; ALT: Alanine aminotransferase; GGT: Gamma glutamyl transpeptidase; IQR: Interquartile range; ECOG-PS: Eastern Cooperative Oncology Group Performance Status; BCLC: Barcelona Clinic Liver Cancer; INR: International normalized ratio; NA: Not available.

¹5 BCLC A patients.